Otsuka Medical Devices and Veryan Medical Announce Completion of Acquisition
Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), a 100% subsidiary of Otsuka
Holdings Co., Ltd., and Veryan Medical Ltd. (“Veryan”) announce the completion of theacquisition of Veryan by Otsuka Medical Devices through its UK subsidiary Otsuka MedicalDevices UK Ltd.
Veryan’s BioMimics 3D peripheral vascular stent received U.S. FDA approval on 4 October,2018. Following the acquisition, Veryan and Otsuka Medical Devices plan to collaborate indeveloping Swirling Flow® stents for use in the treatment of vascular disease. As part of theacquisition, Veryan’s operations in Galway, Ireland, will be retained by Otsuka MedicalDevices and will play a key role in the continued development of the Swirling Flow ®
technology.
Chas Taylor, CEO of Veryan, said: “We are delighted to become part of Otsuka MedicalDevices. This will allow Veryan to build on the strong clinical data with the BioMimics stentand realise the potential to significantly advance the treatment of peripheral vascular disease.”
Noriko Tojo, CEO of Otsuka Medical Devices commented: “Veryan’s stent technologyrepresents an excellent fit with our existing activities and has considerable future development
potential.”

About Veryan Medical Ltd.
Veryan has developed the BioMimics 3D Vascular Stent System. The BioMimics 3D stent hasa unique three-dimensional helical shape, designed to impart natural curvature to the diseased
femoropopliteal artery, promoting swirling flow and elevating wall shear, which has aprotective effect on the endothelium.1,2,3 The helical shape of the BioMimics 3D stent is also
designed to facilitate shortening of the stented segment during knee flexion and mitigate therisk of stented segment compression causing localised strains that in a straight stent may leadto stent fracture and chronic vascular injury.4,5 Veryan’s Head Office is in Horsham, UK andits Research & Development facility is located in Galway, Ireland. BioMimics 3D and Swirling
Flow are registered trademarks of Veryan Medical Ltd. The BioMimics 3D Vascular Stent
System has FDA and CE Mark approval.
For more information about Veryan Medical, please visit www.veryanmedical.com or contact
Chas Taylor, Veryan’s CEO, at chas.taylor@veryanmed.com, tel +44 (0)1403 258984.

About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices Co., Ltd. focuses on the development and commercialization ofendovascular devices that provide new therapeutic options in areas where patient needs cannot
be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices Co.,
Ltd. is a fully-owned subsidiary of Otsuka Holdings Co., Ltd., a leading global healthcare grouplisted on the Tokyo Stock Exchange (JP 4578). With operations in pharmaceuticals,

nutraceuticals, medical devices and other health-related businesses, the group generated
worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.omd.otsuka.com/en/

http://www.otsuka.com/en/

1. Zeller T. - Oral Presentation VIVA 2014
2. Malek, JAMA, 282, p 2035-2042, 1999
3. Zeller T. et al; Circ Cardiovasc lnterv. 2016;94. BH Smouse et al, Endovasc. Today, vol 4, no. 6, pp. 60-66, 2005
5. Scheinert D et al, J Am Coll Cardiol 2005;45:312-5